Clinical Trial Search

Primary: Adjusted Mean Monthly Percent of Days Covered With B-blocker Following Intervention Date — 66.37; 70.62 Adjusted monthly % of days covered

Primary: Maximum Tolerated Dose and Toxicity Profile

Primary: Emergence Agitation — 6; 0 participants

Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08

Primary: Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) — -1.42; -1.36 percentage of glycosylated hemoglobin — p=<0.001

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 93.2; 27.3; 85.2 percentage of participants

Primary: Cognitive Performance — 4.97; -2.30 units on a scale

Primary: Time From First Dose to Urinary Continence — NA; NA days — p=0.1745

Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR)24 — 61.9 percentage of participants

Primary: Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD) — 2.26; 1.45; 2.50 percent change

Primary: • Evaluate the Effectiveness of the PillCam COLON 2 Bowel Prep Regimen in Crohn's Disease Patients — 62; 79 percentage of participants

Primary: Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) — -0.352; -0.460 percentage of glycosylated hemoglobin — p=0.055

Primary: Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax) — 19.5; 5.78 nanogram per milliliter (ng/mL)

Primary: Incidence of Acute Otitis Media — 30; 27 participants with AOM

Primary: Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril — 1580; 1740; 1660; 1720 (nanograms*hours/milliliter)/milligram